Physician profile
Sara Karamloo
NPI 1396989489
$4,297.17
in general payments reported to CMS, 2019-2025
38 companies · $736 in 2025
The $736 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $459 · 2021: $651 · 2022: $976 · 2023: $455 · 2024: $646 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,388.96 | 2019-2025 | Collagenase Santyl, Stravix, Grafix |
| Musculoskeletal Transplant Foundation INC. | $622.90 | 2020-2023 | |
| Amgen INC. | $354.07 | 2024-2025 | Krystexxa |
| Organogenesis INC. | $275.57 | 2020-2024 | Puraply |
| Orthofix Medical, INC. | $194.29 | 2019-2025 | Physio-Stim, Accelstim |
| Paratek Pharmaceuticals, INC. | $155.89 | 2022-2025 | Nuzyra |
| Bioventus LLC | $153.03 | 2019-2024 | Exogen Ultrasound Bone Healing System |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $132.62 | 2019-2023 | Jublia |
| Horizon Therapeutics Plc | $130.45 | 2019-2022 | |
| Convatec INC. | $112.01 | 2022-2024 | |
| Biotissue Holdings INC. | $71.18 | 2023-2024 | |
| Mimedx Group, INC. | $68.76 | 2024 | |
| Depuy Synthes Sales INC. | $51.81 | 2025 | Motoband |
| Medtronic, INC. | $48.81 | 2022-2025 | Rapidvac |
| Stryker Corporation | $39.81 | 2025 | Ortholoc 3di, Actishield |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Molnlycke Health Care US, LLC | $38.58 | 2025 | Mextra Superabsorbant, Mepilex Border Flex, Exufiber |
| Treace Medical Concepts, INC. | $37.75 | 2022 | |
| Reprise Biomedical, INC. | $37.69 | 2024 | Miro3d |
| Zyla Life Sciences, INC. | $29.44 | 2019 | |
| Globus Medical, INC. | $29.01 | 2025 | Senza |
| Sandoz INC. | $24.74 | 2019 | |
| Alfasigma USA, INC. | $23.25 | 2021 | |
| Grt US Holding, INC. | $22.60 | 2022 | |
| Bard Peripheral Vascular, INC. | $22.28 | 2021 | |
| Triad Life Sciences INC. | $22.22 | 2022 | |
| Derma Sciences, INC. | $19.50 | 2019 | |
| Osiris Therapeutics INC. | $18.36 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.18 | 2022 | |
| Melinta Therapeutics, LLC | $17.89 | 2022 | |
| Hartmann USA, INC. | $17.59 | 2023 | Zetuvit Plus |
| Curonix LLC | $17.03 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Resmed Corp | $16.52 | 2022 | |
| Amniox Medical, INC. | $16.38 | 2020 | |
| Integra Lifesciences Corporation | $14.67 | 2020 | |
| Misonix INC | $14.45 | 2021 | |
| Arthrosurface Incorporated | $14.08 | 2019 | |
| Nevro Corp. | $13.70 | 2023 | Senza |
| Medline Industries Lp | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Karamloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.